Observational, Epidemiological and Non Interventional Study Evaluating the Evolution of Lung Cancer Related Symptoms and Its Correlation With Disease Control Rate in Patients With Non-Small Cell Lung Cancer (NSCLC) Initiating First-line Treatment With Platinum Based Standard Chemotherapy.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 156
- 主要终点
- Change in lung cancer related symptoms (LCSS questionnaire)
研究概览
简要总结
This prospective observational study will evaluate the evolution of lung cancer related symptoms and their correlation with the disease control rate (complete response, partial response and stable disease) in patients with non-small cell lung cancer initiating first-line treatment with standard platinum-based chemotherapy with or without Avastin (bevacizumab). Data will be collected from each patient at baseline and after 4-6 cycles of chemotherapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients, >/= 18 years of age
- •Histologically or cytologically confirmed non-small cell lung cancer
- •Initiating first-line treatment with standard platinum-based chemotherapy, with or without bevacizumab
排除标准
- •Contraindications to the use of platinum-based chemotherapy
结局指标
主要结局
Change in lung cancer related symptoms (LCSS questionnaire)
时间窗: up to approximately 6 months (4-6 cycles of chemotherapy)
Correlation of lung cancer related symptoms and disease control rate (complete response, partial response, stable disease according to RECIST criteria)
时间窗: approximately 2 years
次要结局
- Frequency/severity of lung cancer related symptoms (LCSS questionnaire)(approximately 2 years)